Abstract
The number of software - mobile applications intended for use in the field of people’s health and well-being is constantly increasing. The aim of this review is to compare regulations on software – mobile applications as medical devices in the United States of America (USA), European Union (EU) and Serbia, with reference on the efforts for international harmonization of the regulations. The goal is to increase awareness of the broader healthcare professionals’ (HCPs) audience about this topic. Publicly available information from official regulatory bodies websites was analyzed and synthesized for two regions and one country of interest. The results show differences in regulatory approaches in this area between two biggest medical device markets – the USA and the EU, while regulations in Serbia are being harmonized with the EU. Regulations clearly define criteria that software – mobile application needs to meet to be assessed as a medical device; on the other hand, they leave a number of applications that provide health-related services out of the regulated scope. Based on the increased awareness of regulations, recommendations for future research can be directed towards greater involvement of HCPs in patient counseling and decision making regarding the selection of mobile applications, to prevent the use of inadequate mobile applications and ensure that their patients are correctly using the right applications with positive effects on health and well-being.
Keywords
Array
Array
Array
Array
References
About IMDRF [Internet]. International Medical Device Regulators Forum (IMDRF); c2022 [cited 2022 Feb 11]. Available from: http://www.imdrf.org/about/about.asp
International Medical Device Regulators Forum. IMDRF SaMD Working Group. Software as a Medical Device (SaMD): Key Definitions. IMDRF, 2013.
Status of the Global Medical Device Market [Internet]. Korea Health Industry Development Institute; c2022 [cited 2022 Feb 11]. Available from:
Part II: 1938, Food, Drug, Cosmetic Act [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/part-ii-1938-food-drug-cosmetic-act
Part III: Drugs and Foods Under the 1938 Act and Its Amendments [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/part-iv-regulating-cosmetics-devices-and-veterinary-medicine-after-1938
Milestones in U.S. Food and Drug Law History [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/milestones-us-food-and-drug-law-history
21st Century Cures Act [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act
FD&C Act Reference Information [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act
United States Code: Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-399.
United States Code: Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360j (o).
United States Code: Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360c.
How to Determine if Your Product is a Medical Device [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Feb 11]. Available from: https://www.fda.gov/medical-devices/classify-your-medical-device/how-determine-if-your-product-medical-device#step1
U.S. Food & Drug Administration. Policy for Device Software Functions and Mobile Medical Applications. Guidance for Industry and Food and Drug Administration Staff. U.S. Food & Drug Administration, 2019.
Medica Device Sector, New Regulations [Internet]. European Commission; c2022 [cited 2022 Feb 11]. Available from: https://ec.europa.eu/health/medical-devices-sector/new-regulations_en
Directive 90/385/EEC. Official Journal of the European Communities, L 189, 20.7.1990, p.17.
Directive 93/42/EEC. Official Journal of the European Communities, L 169, 12.7.1993, p. 1.
Directive 98/79/EC. Official Journal of the European Communities, L 331, 7.12.1998, p. 1.
Regulation (EU) 2017/745. Official Journal of the European Communities, L 117 5.5.2017, p. 1.
Regulation (EU) 2017/746. Official Journal of the European Communities, L 117 5.5.2017, p. 176.
Regulation (EU) 2020/561. Official Journal of the European Communities, L 130, 24.4.2020, p. 18–22.
Regulation (EU) 2022/112. Official Journal of the European Communities, L 19, 28.1.2022, p. 3–6.
European Commission. Medical Devices: Guidance document - Qualification and Classification of standalone software. EC, MEDDEV 2.1/6, 2016.
European Commission, Working group on borderline and classification. Manual on borderline and classification in the community regulatory framework for medical devices. EC, Version 1.22, 2019.
Medical Device Coordination Group Document. Guidance on Qualification and Classification of Software in Regulation (EU) 2017/745 – MDR and Regulation (EU) 2017/746 – IVDR. MDCG 2019-11
MHRA, Guidance: Medical device stand-alone software including apps (including IVDMDs), v1.08, 2021.
Law on medical devices. Official Gazette of the RS, No. 105/2017.
Rulebook on essential requirements for medical devices. Official Gazette of the RS, No. 65/2018.
Medical Devices Registry [Internet]. Medicines and Medical Devices Agency of Serbia; [cited 2022 Feb 11]. Available from: https://ms.alims.gov.rs/pages/view-registarmedicinskihsredstava
- Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
- Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.
- Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).